Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP3698652B2 - Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same - Google Patents
[go: Go Back, main page]

JP3698652B2 - Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same - Google Patents

Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same Download PDF

Info

Publication number
JP3698652B2
JP3698652B2 JP2001074044A JP2001074044A JP3698652B2 JP 3698652 B2 JP3698652 B2 JP 3698652B2 JP 2001074044 A JP2001074044 A JP 2001074044A JP 2001074044 A JP2001074044 A JP 2001074044A JP 3698652 B2 JP3698652 B2 JP 3698652B2
Authority
JP
Japan
Prior art keywords
sugar
solid preparation
low
bulk density
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001074044A
Other languages
Japanese (ja)
Other versions
JP2001328948A (en
Inventor
史枝 丹野
栄 尾原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Etsu Chemical Co Ltd
Original Assignee
Shin Etsu Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Etsu Chemical Co Ltd filed Critical Shin Etsu Chemical Co Ltd
Priority to JP2001074044A priority Critical patent/JP3698652B2/en
Publication of JP2001328948A publication Critical patent/JP2001328948A/en
Application granted granted Critical
Publication of JP3698652B2 publication Critical patent/JP3698652B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、口腔内の唾液又は少量の水により速やかに口腔内で崩壊する固形製剤に関するものである。
【0002】
【従来の技術】
近年、嚥下能力が低い高齢者や小児などの患者のために、易服用・易投与な固形製剤が望まれている。具体的には、口腔内崩壊性製剤、ゼリー状製剤、ペースト状製剤等が挙げられるが、特に口腔内崩壊錠剤は水なしであるいは少量の水により服用することが可能であり、簡便にかつ比較的容易に服用することができ高齢者や小児などに適した剤形となり得る。
【0003】
これまでにも様々な口腔内崩壊性製剤が提案されている。例えば、特公昭62−50445号公報には薬物、ゼラチンなどのポリマー水溶液をPTP(Press Through Package)ポケットに充填して凍結乾燥することにより製造される口腔内崩壊性錠剤及びその製造方法が提案されている。しかしながら、この方法では、特殊な製造工程が必要であり、得られる錠剤の強度が小さく取り扱いに問題があった。
【0004】
また、特開平5−271054号公報では、薬物、糖類及び適当な水分を含む練合物を低圧で打錠した後、乾燥した口腔内崩壊錠剤及びその製造方法が提案されているが、打錠の際、臼・杵等に練合物が付着しやすく、製造工程での水分管理が困難であるといった問題があるため、大量生産には適していない。
【0005】
一方、特開平8―291051号公報及び特開平9−48726号公報には、糖類・糖アルコール類、水溶性結合剤と薬物等を混合して低圧で打錠した後、錠剤強度の増大のために加湿下で錠剤を湿潤させ、次いで乾燥した口腔内崩壊性錠剤及びその製造方法が提案されているが、製造工程が多段階になること、加湿工程で錠剤の外観が変化し商品価値が損なわれる、さらに湿度に不安定な薬物や潮解性を示す薬物には適さない等の問題があった。
【0006】
こうした特殊な製剤技術を必要とせず、一般的な設備で口腔内崩壊性製剤を調製する方法も幾つか提案されている。特開平9−71523号公報では、薬物と崩壊剤として低置換度ヒドロキシプロピルセルロース、賦形剤として結晶セルロース及び滑沢剤からなる混合物を低圧で打錠した口腔内崩壊錠剤が提案されている。しかし、セルロース系やポリビニルピロリドン系の添加剤を多く使用するため、錠剤の崩壊性、溶解性、舌触り、味において実用上劣るという欠点が生じる。
【0007】
特開平11−43429号公報には、薬物、糖及び置換度の限定された低置換度ヒドロキシプロピルセルロースからなる口腔内崩壊錠剤が提案されているが、錠剤の舌触り、味の改善は充分ではなかった。
【0008】
【発明が解決しようとする課題】
本発明は、口腔内の唾液又は少量の水と共に服用することにより、口腔内で速やかに崩壊し、製造工程が容易で、かつ製造時や流通過程において成形性を保持しうる適度な強度を有する固形製剤及びその製造方法を提供することを目的とする。
【0009】
【課題を解決するための手段】
本発明者らは、ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上である低置換度ヒドロキシプロピルセルロース及び糖・糖アルコールを含有する固形製剤を用いることにより、固形製剤に適度な強度を与えるとともにに口腔内で味の不快感を感じることなく、速やかに薬物が崩壊することを見出し、本発明をなすに至ったものである。
即ち、ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上である低置換度ヒドロキシプロピルセルロース及び糖・糖アルコールを含有することを特徴とする固形製剤及びその製造方法を提供する。
また、ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上で、かつ乾式レーザー回折法による体積平均粒子径が30ミクロン以上である低置換度ヒドロキシプロピルセルロースを粉砕して得られる体積平均粒子径が25ミクロン以下の低置換度ヒドロキシプロピルセルロース及び糖・糖アルコールを含有することを特徴とする固形製剤及びその製造方法を提供する。
【0010】
【発明の実施の形態】
本発明における「ゆるめ嵩密度」とは、疎充填の状態の嵩密度をいい、直径5.03cm、高さ5.03cm(容積100ml)の円筒容器(材質:ステンレス)へ試料をJISの24メッシュの篩を通して、上方(23cm)から均一に供給し、上面をすり切って秤量することによって測定される。
一方、「固め嵩密度」とは、これにタッピングを加えて密充填にした場合の嵩密度をいう。ここで、タッピングとは、試料を充填した容器を一定の高さから繰り返し落下させて底部に軽い衝撃を与え、試料を密充填にする操作をいう。実際には、ゆるめ嵩密度を測定する際、上面をすり切って秤量した後、さらにこの容器の上にキャップ(下記ホソカワミクロン社製パウダーテスターの備品)をはめ、この上縁まで粉体を加えてタップ高さ1.8cmのタッピングを180回行う。終了後、キャップを外して容器の上面で粉体をすり切って秤量し、この状態の嵩密度を固め嵩密度とする。これらの操作は、ホソカワミクロン社製パウダーテスター(PT−D)を使用することにより測定できる。
【0011】
本発明の低置換度ヒドロキシプロピルセルロースは、ゆるめ嵩密度が0.40g/ml以上、かつ固め嵩密度が0.60g/ml以上の低置換度ヒドロキシプロピルセルロース、好ましくはこの嵩密度を有する乾式レーザー回折法による平均体積粒子径が30ミクロン以上の低置換度ヒドロキシプロピルセルロースを粉砕するなどして得られるものである。なお、粉砕工程は、常法に従って行われ、例えばボールミル、ハンマーミル、ナイフミル、ジェットミルなどの粉砕機を用いることができる。
本発明にいう乾式レーザー回折法とは、例えばドイツSympatec社のHELOS装置を用いた方法のように、圧縮空気で粉体サンプルを噴出させたものにレーザー光を照射し、その回折強度により体積平均径を測定する方法をいう。体積平均粒径は、例えば「改訂増補粉体物性図説」粉体工学会・日本粉体工業技術協会編、日経技術図書、1985年、第88頁に記載されているように、式{Σ(nD3)/Σn}1/3を用いて計算される。式中、Dは粒子の直径、nはその直径の粒子数、Σnは全粒子数を表す。
【0012】
本発明に用いる低置換度ヒドロキシプロピルセルロースは、セルロースエーテルの一種であり、結合剤として汎用されるヒドロキシプロピルセルロースと類似するが、その性質を異にする。前者と後者の本質的な違いは、ヒドロキシプロポキシル基の含有量にあり、その値は、前者が5〜16.0重量%であるのに対し、後者が53.4〜77.5重量%である。この値は、日本薬局方に収載されている方法で測定し、その範囲は日本薬局方「低置換度ヒドロキシプロピルセルロース」のモノグラフで明確に規定されている。
即ち、低置換度ヒドロキシプロピルセルロースのヒドロキシプロポキシル基の含有量は、5.0〜16.0重量%である。
【0013】
ゆるめ嵩密度が0.40g/ml以上、かつ固め嵩密度が0.60g/ml以上の低置換度ヒドロキシプロピルセルロースは、以下に示す方法により製造することができる。すなわち、パルプをアルカリ溶液に浸漬して、アルカリセルロースとし、これを酸化プロピレンと反応させる。この後の工程において、生成物を水又はアルカリ性に調節した水に投入して、完全溶解させ、ほとんど均一な透明なスラリー状にしてから、塩酸で中和して析出された低置換度ヒドロキシプロピルセルロースを回収後、水で洗浄し乾燥して粉砕する。
ここでいう完全溶解状態とは、生成物がその形状をほぼ完全に失う状態を意味する。すなわち、完全に透明になることはもとより、不透明のスラリー状態や3リットルのスラリー中に5〜10個の割合で生成物小塊の残留が認められる程度も含む。溶解した後の状態は、高粘度のスラリー状であり、ニーダーなどの撹拌力の強い練合機が必要である。この後、塩酸等の酸で中和することにより、低置換度ヒドロキシプロピルセルロースが析出し、このものを回収して洗浄、乾燥、粉砕して製品とする。
【0014】
本発明の好ましい態様として、ゆるめ嵩密度が0.40g/ml以上(より好ましくは0.40g/ml以上0.60g/ml未満)、かつ固め嵩密度が0.60g/ml以上(より好ましくは0.60g/ml以上0.85g/ml未満)、かつ乾式レーザー回折法による平均体積粒子径が30ミクロン以上(より好ましくは30ミクロン以上200ミクロン以下)の低置換度ヒドロキシプロピルセルロースを粉砕して、該回折法による体積平均粒子径が25ミクロン以下の低置換度ヒドロキシプロピルセルロースが用いられる。このようにして得られた低置換度ヒドロキシプロピルセルロースは、ゆるめ嵩密度が0.29g/ml以上(より好ましくは0.29g/ml以上0.55g/ml未満)、固め嵩密度が0.55g/ml以上(より好ましくは0.55g/ml以上0.85g/ml未満)であることが好ましい。
【0015】
本発明における低置換度ヒドロキシプロピルセルロースの添加量は、固形製剤100重量部中に1〜99重量部、好ましくは、5〜50重量部である。低置換度ヒドロキシプロピルセルロースの添加量が1重量部未満だと、錠剤の強度が不十分で取り扱いが困難となり、99重量部を超えると錠剤強度は得られるが、口腔内での崩壊が遅延するおそれがある。
【0016】
本発明において、糖・糖アルコールとは、糖アルコールを含めた広い意味の糖である。糖は、糖類のうち水溶性で甘味をもつものの総称であり単糖類と大多数の少糖類が含まれ、多糖類も加水分解によって糖に帰着するため、糖類に含まれる。糖アルコールは、糖のカルボニル基が還元された鎖上の多価アルコールを指し、類似の性質をもつ環式糖アルコール(シクリトール)も含む。
本発明において、糖・糖アルコールとしては、好ましくは、エリスリトール、ソルビトール、トレハロース、キシリトール、マンニトール、グルコース、白糖などが挙げられ、特に好ましくは、エリスリトール又はソルビトール、トレハロース、キシリトールが挙げられ、これらは、単独又は2種以上混合して使用することもできる。
これらの糖・糖アルコールは、結晶又は粉末で用いられるが、特に平均粒子径が500ミクロン以下のものを用いると、成形性、崩壊性、舌触りの点で優れた特性を示す。
【0017】
糖・糖アルコールの添加量は、固形製剤100重量部中に1〜99重量部、好ましくは10〜90重量部である。糖・糖アルコールの添加量が、1重量部未満だと口腔内での崩壊に時間を要し、99重量部を超えると充分な製剤の強度が得られなくなるおそれがある。
【0018】
また、本発明の固形製剤に加える主成分は、医薬品であれば解熱鎮痛剤、抗生物質、抗炎症剤、ビタミンや栄養物など特に限定はされない。
さらに、他の成分として例えば滑沢剤、結合剤、安定化剤、着色剤、矯味剤などを添加しても良い。
【0019】
本発明の固形製剤の製造方法については、前記の組成物を混合して直接打錠あるいは乾式打錠するか、乾式造粒、流動層造粒あるいは湿式造粒等いずれの方法も適用される。
また、錠剤を製造するための打錠方法は、一般に錠剤を成形又は造粒するための装置を用いて行われ、例えば単発打錠機、ロータリー打錠機、タブレッティングテスターなどが挙げられる。
打錠の際の成形圧力は、通常50〜300MPa、好ましくは80〜200MPaである。成形圧力が50MPaより低いと錠剤硬度が不足し取り扱いが困難となり、300MPaより高いと崩壊が遅延する場合がある。
【0020】
上記のようにして製造された本発明の固形製剤、特に口腔内崩壊錠剤は口腔内での崩壊性に優れ、かつ適度な成形性(強度)を保持する。すなわち、本発明の固形製剤の口腔内崩壊時間(健康な成人の口腔内の唾液で錠剤が完全に崩壊するまでの時間)は、通常1〜60秒、好ましくは1〜40秒、さらに好ましくは1〜30秒程度である。また、錠剤硬度(錠剤硬度計による)は、通常2〜15kgf好ましくは3〜10kgf程度である。
【0021】
本発明における固形製剤には、錠剤、顆粒剤、細粒剤、カプセル剤などが含まれる。
【0022】
【実施例】
以下に本発明の実施例及び比較例を示すが、本発明はこれら実施例の内容のみに限定されるものではない。
実施例1
エリスリトール(日研化学社製)を乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体を70重量部、本発明の低置換度ヒドロキシプロピルセルロース(乾式レーザー法での体積平均粒子径が47ミクロン、ゆるめ嵩密度0.47g/ml、固め嵩密度0.69g/ml、ヒドロキシプロポキシル基含有量11.0重量%)30重量部を混合後、この混合粉末に対して0.5重量%の割合でステアリン酸マグネシウムを配合し、単発打錠機(三共パイオテク社製タブレッティングテスター)を用いて、打錠圧100MPaで11mmφ、1錠480mgの固形製剤を得た。
【0023】
実施例2
エリスリトールを乳鉢で粉砕し、目開きを355ミクロンの篩で篩下した粉体を70重量部、本発明の低置換度ヒドロキシプロピルセルロース(実施例1の低置換度ヒドロキシプロピルセルロースを微粉砕した:乾式レーザー法での体積平均粒子径が16ミクロン)30重量部を混合後、この混合粉末に対して0.5重量%の割合でステアリン酸マグネシウムを配合し、単発打錠機を用いて打錠圧100MPaで11mmφ、1錠480mgの固形製剤を得た。
【0024】
実施例3
エリスリトールを乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体70重量部に、実施例1の低置換度ヒドロキシプロピルセルロース30重量部を混合し、流動層造粒機(パウレック社製マルチプレックスMP−01)を用いて、精製水を噴霧し、流動層造粒を行った。続いて、得られた造粒末に対して0.5重量%の割合でステアリン酸マグネシウムを配合し、単発打錠機を用いて打錠圧100MPaで11mmφ、1錠480mgの固形製剤を得た。
【0025】
実施例4
エリスリトールを乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体70重量部に、実施例2の低置換度ヒドロキシプロピルセルロース30重量部を混合し、流動層造粒機(パウレック社製マルチプレックスMP−01)を用いて、精製水を噴霧し、流動層造粒を行った。続いて、得られた造粒末に対して0.5重量%の割合でステアリン酸マグネシウムを配合し、単発打錠機を用いて打錠圧100MPaで11mmφ、1錠480mgの固形製剤を得た。
【0026】
実施例5
打錠圧を200MPaに変えた以外は、実施例4と同様の方法で口腔内崩壊錠剤を得た。
【0027】
比較例1
エリスリトールを乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体に0.5重量%のステアリン酸マグネシウムを配合し、単発打錠機を用いて打錠圧100MPaで11mmφ、1錠480mgの固形製剤を得た。
【0028】
比較例2
エリスリトールを乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体70重量部に低置換度ヒドロキシプロピルセルロース(信越化学工業社製LH―21、乾式レーザー法での体積平均粒子径が37ミクロン、ゆるめ嵩密度0.335g/ml固め嵩密度0.597g/ml、ヒドロキシプロポキシル基含有量が10.9重量%)30重量部を混合し、この混合粉末に対して0.5重量%の割合でステアリン酸マグネシウムを配合し、単発打錠機を用いて打錠圧100MPaで11mmφ、1錠480mgの口腔内崩壊錠剤を得た。
【0029】
比較例3
エリスリトールを乳鉢で粉砕し、目開き355ミクロンの篩で篩下した粉体を70重量部に比較例2の低置換度ヒドロキシプロピルセルロース30重量部を混合し、精製水を噴霧して流動層造粒を行った。続いて、得られた造粒末に対して0.5重量%の割合でステアリン酸マグネシウムを配合した後、単発打錠機にて打錠圧100MPaで11mmφ、1錠480mgの口腔内崩壊錠剤を得た。
【0030】
比較例4
比較例3の低置換度ヒドロキシプロピルセルロースを(信越化学工業社製LH−31、乾式レーザー法での体積平均粒子径が17ミクロン、ゆるめ嵩密度0.323g/ml固め嵩密度0.623g/ml、ヒドロキシプロポキシル含有量が10.9重量%)に変えた以外は同様の方法で、口腔内崩壊錠を得た。
【0031】
比較例5
比較例3の低置換度ヒドロキシプロピルセルロースを(信越化学工業社製LH―32、乾式レーザー法での体積平均粒子径が18ミクロン、ゆるめ嵩密度0.306g/ml固め嵩密度0.582g/ml、ヒドロキシプロポキシル基含有量が8.3重量%)に変えた以外は、同様の方法で口腔内崩壊錠剤を得た。
【0032】
実施例1〜5及び比較例1〜5の口腔内崩壊錠剤の硬度と崩壊時間とを測定し、その結果を表1に示す。なお、口腔内崩壊錠剤の硬度は、錠剤硬度計(エルヴェカ硬度計)を用い、崩壊時間の測定には日本薬局方崩壊試験機(試験液:水、37℃)を使用し、n=6(nは試料数を表す。)で測定を行った。口腔内崩壊時間は、健康な成人男女5人で試験し、口腔内で錠剤を噛まずに軽く口に含んだ状態で、錠剤が完全に溶解又は崩壊するまでの時間を測定し、平均値を算出した。また、この時の服用感も併せて評価した。評価は、良好(◎)、やや良好(○)、普通(△)、不良(×)の四段階とした。
表1の結果から、硬度と崩壊時間の関係において、本発明の固形製剤は、崩壊時間が速く、口腔内の触感も良好なものが得られた。
【0033】
【発明の効果】
本発明の固形製剤によれば、成形性及び崩壊性に優れた特徴を有するため、嚥下力の弱い高齢者や小児が容易に服用することができる。
【0034】
【表1】

Figure 0003698652
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a solid preparation that rapidly disintegrates in the oral cavity by saliva or a small amount of water in the oral cavity.
[0002]
[Prior art]
In recent years, easy-to-administer and easy-to-administer solid preparations are desired for patients such as elderly people and children who have low swallowing ability. Specifically, oral disintegrating preparations, jelly-like preparations, paste-like preparations and the like can be mentioned. In particular, orally disintegrating tablets can be taken without water or with a small amount of water. It can be taken easily and can be a dosage form suitable for the elderly and children.
[0003]
Various oral disintegrating preparations have been proposed so far. For example, Japanese Patent Publication No. 62-50445 proposes an orally disintegrating tablet produced by filling a PTP (Press Through Package) pocket with an aqueous polymer solution such as a drug or gelatin and freeze-drying the same, and a method for producing the same. ing. However, this method requires a special manufacturing process, and the strength of the resulting tablet is small, causing a problem in handling.
[0004]
Japanese Patent Application Laid-Open No. 5-271044 proposes a tablet that is prepared by compressing a kneaded product containing a drug, a saccharide and appropriate moisture at low pressure and then dried, and a method for producing the tablet. At this time, the kneaded material tends to adhere to the mortar, pestle, etc., and it is difficult to control the moisture in the manufacturing process, so it is not suitable for mass production.
[0005]
On the other hand, in JP-A-8-291051 and JP-A-9-48726, a saccharide / sugar alcohol, a water-soluble binder and a drug are mixed and compressed at a low pressure, and then the tablet strength is increased. Proposals have been made on orally disintegrating tablets that have been wetted and then dried, and a method for producing the same, but the manufacturing process is multistage, the appearance of the tablets changes in the humidifying process, and the commercial value is impaired. Furthermore, there are problems such as being unsuitable for drugs that are unstable to humidity and drugs that exhibit deliquescence.
[0006]
Several methods for preparing an orally disintegrating preparation using general equipment without requiring such a special preparation technique have been proposed. Japanese Patent Application Laid-Open No. 9-71523 proposes an orally disintegrating tablet obtained by tableting a mixture of a drug and a low-substituted hydroxypropyl cellulose as a disintegrant and crystalline cellulose and a lubricant as excipients at a low pressure. However, since many cellulose-based and polyvinylpyrrolidone-based additives are used, there is a disadvantage that the disintegration, solubility, texture, and taste of the tablet are practically inferior.
[0007]
Japanese Patent Application Laid-Open No. 11-43429 proposes an orally disintegrating tablet composed of a drug, a sugar, and a low-substituted hydroxypropylcellulose having a limited degree of substitution, but the improvement in the touch and taste of the tablet is not sufficient. It was.
[0008]
[Problems to be solved by the invention]
The present invention, when taken together with saliva or a small amount of water in the oral cavity, disintegrates rapidly in the oral cavity, has an appropriate strength that allows easy manufacturing processes and can maintain moldability during manufacturing and distribution. It aims at providing a solid formulation and its manufacturing method.
[0009]
[Means for Solving the Problems]
The present inventors use a solid preparation containing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g / ml or more and a hard bulk density of 0.60 g / ml or more and a sugar / sugar alcohol. Thus, it was found that the drug rapidly disintegrates without giving an unpleasant taste in the oral cavity while giving the solid preparation an appropriate strength, and has led to the present invention.
That is, a solid preparation characterized by containing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g / ml or more and a hard bulk density of 0.60 g / ml or more and sugar / sugar alcohol, and A manufacturing method is provided.
Further, a low substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g / ml or more, a hardened bulk density of 0.60 g / ml or more, and a volume average particle diameter by dry laser diffraction of 30 microns or more. A solid preparation characterized by containing a low-substituted hydroxypropyl cellulose having a volume average particle size of 25 microns or less obtained by pulverization and a sugar / sugar alcohol, and a method for producing the same.
[0010]
DETAILED DESCRIPTION OF THE INVENTION
“Loose bulk density” in the present invention means a bulk density in a loosely packed state, and a sample is placed in a cylindrical container (material: stainless steel) having a diameter of 5.03 cm and a height of 5.03 cm (volume: 100 ml) according to JIS 24 mesh. It is measured by feeding uniformly from above (23 cm) through a sieve and grinding the top surface.
On the other hand, the “hardened bulk density” refers to the bulk density when tapping is added to form a close packing. Here, tapping refers to an operation in which a sample-filled container is repeatedly dropped from a certain height to give a light impact to the bottom, thereby filling the sample tightly. Actually, when measuring the loose bulk density, weigh the upper surface and weigh it, then put a cap (equipment of Hosokawa Micron's powder tester below) on this container and add the powder to this upper edge. Tapping with a tap height of 1.8 cm is performed 180 times. After completion, the cap is removed, the powder is ground on the upper surface of the container and weighed, and the bulk density in this state is hardened to obtain the bulk density. These operations can be measured by using a powder tester (PT-D) manufactured by Hosokawa Micron.
[0011]
The low-substituted hydroxypropylcellulose of the present invention is a low-substituted hydroxypropylcellulose having a loose bulk density of 0.40 g / ml or more and a hardened bulk density of 0.60 g / ml or more, preferably a dry laser having this bulk density. It is obtained by pulverizing low-substituted hydroxypropylcellulose having a mean volume particle diameter of 30 microns or more by a diffraction method. The pulverization step is performed according to a conventional method, and for example, a pulverizer such as a ball mill, a hammer mill, a knife mill, or a jet mill can be used.
The dry laser diffraction method referred to in the present invention is, for example, a method in which a powder sample is ejected with compressed air, such as a method using a HELOS apparatus of Sympatec, Germany, and a volume average is calculated based on the diffraction intensity. A method of measuring the diameter. The volume average particle diameter can be determined by the formula {Σ (Summary), as described in, for example, “Revised Supplementary Powder Physical Properties”, Powder Engineering Society, Japan Powder Industrial Technology Association, Nikkei Technical Book, 1985, p. 88. nD 3 ) / Σn} 1/3 . In the formula, D is the diameter of the particle, n is the number of particles of that diameter, and Σn is the total number of particles.
[0012]
The low-substituted hydroxypropyl cellulose used in the present invention is a kind of cellulose ether, which is similar to hydroxypropyl cellulose widely used as a binder, but has different properties. The essential difference between the former and the latter is the content of hydroxypropoxyl group, which is 5 to 16.0% by weight for the former and 53.4 to 77.5% by weight for the latter. It is. This value is measured by the method listed in the Japanese Pharmacopoeia, and the range is clearly defined in the monograph of the Japanese Pharmacopoeia “low-substituted hydroxypropylcellulose”.
That is, the content of the hydroxypropoxyl group of the low-substituted hydroxypropyl cellulose is 5.0 to 16.0% by weight.
[0013]
Low-substituted hydroxypropylcellulose having a loose bulk density of 0.40 g / ml or more and a hardened bulk density of 0.60 g / ml or more can be produced by the following method. That is, the pulp is immersed in an alkali solution to obtain alkali cellulose, which is reacted with propylene oxide. In the subsequent step, the product is put into water or water adjusted to alkalinity, completely dissolved and made into an almost uniform transparent slurry, and then neutralized with hydrochloric acid and precipitated. After collecting the cellulose, it is washed with water, dried and pulverized.
The completely dissolved state here means a state in which the product loses its shape almost completely. That is, not only it becomes completely transparent, but also includes an opaque slurry state and a degree in which a product lump remains at a rate of 5 to 10 in a 3 liter slurry. The state after dissolution is a high-viscosity slurry, and a kneader with strong stirring power such as a kneader is required. Thereafter, neutralization with an acid such as hydrochloric acid causes precipitation of low-substituted hydroxypropylcellulose, which is recovered, washed, dried and pulverized to obtain a product.
[0014]
As a preferred embodiment of the present invention, the loose bulk density is 0.40 g / ml or more (more preferably 0.40 g / ml or more and less than 0.60 g / ml), and the firm bulk density is 0.60 g / ml or more (more preferably). 0.60 g / ml or more and less than 0.85 g / ml) and a low-substituted hydroxypropyl cellulose having an average volume particle diameter of 30 microns or more (more preferably 30 microns or more and 200 microns or less) by dry laser diffraction is pulverized. A low-substituted hydroxypropylcellulose having a volume average particle diameter of 25 microns or less by the diffraction method is used. The low-substituted hydroxypropylcellulose thus obtained has a loose bulk density of 0.29 g / ml or more (more preferably 0.29 g / ml or more and less than 0.55 g / ml) and a hardened bulk density of 0.55 g. / Ml or more (more preferably 0.55 g / ml or more and less than 0.85 g / ml).
[0015]
The addition amount of the low-substituted hydroxypropyl cellulose in the present invention is 1 to 99 parts by weight, preferably 5 to 50 parts by weight, in 100 parts by weight of the solid preparation. If the amount of low-substituted hydroxypropylcellulose added is less than 1 part by weight, the strength of the tablet is insufficient and handling becomes difficult. If it exceeds 99 parts by weight, tablet strength is obtained, but disintegration in the oral cavity is delayed. There is a fear.
[0016]
In the present invention, sugar / sugar alcohol is a broad meaning sugar including sugar alcohol. Sugar is a general term for saccharides that are water-soluble and sweet, and includes monosaccharides and most oligosaccharides, and polysaccharides are also included in saccharides because they result in hydrolysis. Sugar alcohol refers to a polyhydric alcohol on a chain in which the carbonyl group of the sugar is reduced, and includes cyclic sugar alcohol (cyclitol) having similar properties.
In the present invention, the sugar / sugar alcohol is preferably erythritol, sorbitol, trehalose, xylitol, mannitol, glucose, sucrose, etc., particularly preferably erythritol or sorbitol, trehalose, xylitol. It can also be used alone or in combination.
These sugars / sugar alcohols are used in the form of crystals or powders, and particularly when those having an average particle diameter of 500 microns or less are used, they exhibit excellent characteristics in terms of moldability, disintegration, and touch.
[0017]
The amount of sugar / sugar alcohol added is 1 to 99 parts by weight, preferably 10 to 90 parts by weight, per 100 parts by weight of the solid preparation. If the amount of sugar / sugar alcohol added is less than 1 part by weight, it takes time to disintegrate in the oral cavity, and if it exceeds 99 parts by weight, sufficient strength of the preparation may not be obtained.
[0018]
Moreover, if the main component added to the solid formulation of this invention is a pharmaceutical, there will be no limitation in particular, such as an antipyretic analgesic, an antibiotic, an anti-inflammatory agent, a vitamin, and a nutrient.
Furthermore, you may add a lubricant, a binder, a stabilizer, a coloring agent, a corrigent etc. as another component.
[0019]
As for the method for producing the solid preparation of the present invention, any method such as direct tableting or dry tableting by mixing the above composition, dry granulation, fluidized bed granulation or wet granulation can be applied.
Moreover, the tableting method for manufacturing a tablet is generally performed using an apparatus for molding or granulating a tablet, and examples thereof include a single tableting machine, a rotary tableting machine, and a tableting tester.
The molding pressure at the time of tableting is usually 50 to 300 MPa, preferably 80 to 200 MPa. If the molding pressure is lower than 50 MPa, tablet hardness is insufficient and handling becomes difficult, and if it is higher than 300 MPa, disintegration may be delayed.
[0020]
The solid preparation of the present invention produced as described above, particularly the orally disintegrating tablet, is excellent in disintegration property in the oral cavity and retains an appropriate moldability (strength). That is, the oral disintegration time of the solid preparation of the present invention (the time until the tablet is completely disintegrated with saliva in the oral cavity of a healthy adult) is usually 1 to 60 seconds, preferably 1 to 40 seconds, more preferably It is about 1 to 30 seconds. The tablet hardness (according to the tablet hardness meter) is usually about 2 to 15 kgf, preferably about 3 to 10 kgf.
[0021]
The solid preparation in the present invention includes tablets, granules, fine granules, capsules and the like.
[0022]
【Example】
Examples and Comparative Examples of the present invention are shown below, but the present invention is not limited to the contents of these Examples.
Example 1
70 parts by weight of powder obtained by pulverizing erythritol (manufactured by Nikken Chemical Co., Ltd.) in a mortar and sieving with a sieve having an opening of 355 microns, and the low-substituted hydroxypropylcellulose of the present invention (volume average particle diameter by dry laser method) Is 47 microns, loose bulk density 0.47 g / ml, solid bulk density 0.69 g / ml, hydroxypropoxyl group content 11.0% by weight) is mixed with 30 parts by weight, and 0.5 wt. Magnesium stearate was blended at a ratio of% by weight, and using a single tableting machine (Tabletting tester manufactured by Sankyo Piotech Co., Ltd.), a solid preparation of 11 mmφ and 1 tablet 480 mg at a tableting pressure of 100 MPa was obtained.
[0023]
Example 2
Erythritol was pulverized in a mortar, and 70 parts by weight of powder obtained by sieving with a 355 micron sieve was used. The low-substituted hydroxypropylcellulose of the present invention (the low-substituted hydroxypropylcellulose of Example 1 was finely pulverized: After mixing 30 parts by weight of the volume average particle diameter by dry laser method (16 microns), magnesium stearate is blended at a ratio of 0.5% by weight with respect to the mixed powder, and tableting is performed using a single tableting machine. A solid preparation of 11 mmφ and 1 tablet 480 mg was obtained at a pressure of 100 MPa.
[0024]
Example 3
30 parts by weight of low-substituted hydroxypropylcellulose of Example 1 was mixed with 70 parts by weight of powder obtained by pulverizing erythritol in a mortar and sieved with a sieve having an opening of 355 microns, and a fluidized bed granulator (manufactured by POWREC Co., Ltd.). Using purified multiplex MP-01), purified water was sprayed to perform fluidized bed granulation. Subsequently, magnesium stearate was blended in a proportion of 0.5% by weight with respect to the obtained granulated powder, and a solid preparation of 11 mmφ, 1 tablet 480 mg at a tableting pressure of 100 MPa was obtained using a single tableting machine. .
[0025]
Example 4
30 parts by weight of low substituted hydroxypropylcellulose of Example 2 was mixed with 70 parts by weight of erythritol ground in a mortar and sieved with a 355 micron sieve, and a fluidized bed granulator (Powrec Co., Ltd.). Using purified multiplex MP-01), purified water was sprayed to perform fluidized bed granulation. Subsequently, magnesium stearate was blended in a proportion of 0.5% by weight with respect to the obtained granulated powder, and a solid preparation of 11 mmφ, 1 tablet 480 mg at a tableting pressure of 100 MPa was obtained using a single tableting machine. .
[0026]
Example 5
An orally disintegrating tablet was obtained in the same manner as in Example 4 except that the tableting pressure was changed to 200 MPa.
[0027]
Comparative Example 1
Erythritol was pulverized in a mortar, mixed with 0.5% by weight of magnesium stearate in a powder sieved with a 355-micron sieve, 11 mmφ at a tableting pressure of 100 MPa, 480 mg using a single tableting machine. A solid formulation was obtained.
[0028]
Comparative Example 2
Erythritol was pulverized in a mortar and sieved with a sieve having an opening of 355 microns, and 70 parts by weight of the powder was low-substituted hydroxypropylcellulose (LH-21 manufactured by Shin-Etsu Chemical Co., Ltd., volume average particle size 37 by dry laser method). 30 parts by weight of micron, loose bulk density 0.335 g / ml, solid bulk density 0.597 g / ml, hydroxypropoxyl group content 10.9% by weight), and 0.5% by weight based on the mixed powder In this ratio, magnesium stearate was blended, and an orally disintegrating tablet of 11 mmφ and 1 tablet 480 mg was obtained at a tableting pressure of 100 MPa using a single tableting machine.
[0029]
Comparative Example 3
Erythritol was pulverized in a mortar, and 70 parts by weight of the powder obtained by sieving with a sieve having an opening of 355 microns was mixed with 30 parts by weight of low-substituted hydroxypropylcellulose of Comparative Example 2, and purified water was sprayed to form a fluidized bed. Done the grain. Subsequently, after blending magnesium stearate in a proportion of 0.5% by weight with respect to the obtained granulated powder, a tableting pressure of 100 MPa and 11 mmφ, 1 tablet of 480 mg orally disintegrating tablet was obtained with a single tableting machine. Obtained.
[0030]
Comparative Example 4
The low-substituted hydroxypropylcellulose of Comparative Example 3 (LH-31 manufactured by Shin-Etsu Chemical Co., Ltd., volume average particle diameter by dry laser method is 17 microns, loose bulk density 0.323 g / ml, consolidated bulk density 0.623 g / ml) Orally disintegrating tablets were obtained in the same manner except that the hydroxypropoxyl content was changed to 10.9% by weight.
[0031]
Comparative Example 5
The low-substituted hydroxypropyl cellulose of Comparative Example 3 (LH-32 manufactured by Shin-Etsu Chemical Co., Ltd., volume average particle diameter by dry laser method is 18 microns, loose bulk density 0.306 g / ml, consolidated bulk density 0.582 g / ml) Orally disintegrating tablets were obtained in the same manner except that the hydroxypropoxyl group content was changed to 8.3% by weight.
[0032]
The hardness and disintegration time of the orally disintegrating tablets of Examples 1 to 5 and Comparative Examples 1 to 5 were measured, and the results are shown in Table 1. The hardness of the orally disintegrating tablet was measured using a tablet hardness tester (Elveca hardness tester), the disintegration time was measured using a Japanese Pharmacopoeia disintegration tester (test solution: water, 37 ° C.), and n = 6 ( n represents the number of samples.) The oral disintegration time was tested in 5 healthy adult men and women, and the time until the tablet completely dissolved or disintegrated was measured while the tablet was lightly contained in the mouth without chewing in the oral cavity. Calculated. In addition, the feeling of taking at this time was also evaluated. The evaluation was made in four stages: good ()), slightly good (◯), normal (Δ), and poor (×).
From the results of Table 1, in the relationship between hardness and disintegration time, the solid preparation of the present invention had a fast disintegration time and a good mouth feel.
[0033]
【The invention's effect】
According to the solid preparation of the present invention, since it has characteristics excellent in moldability and disintegration, it can be easily taken by elderly people and children with weak swallowing power.
[0034]
[Table 1]
Figure 0003698652

Claims (5)

ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上である低置換度ヒドロキシプロピルセルロース及び糖・糖アルコールを含有することを特徴とする固形製剤であって、上記糖・糖アルコールが、エリスリトール、ソルビトール、トレハロース、キシリトール、マンニトール、グルコースからなる一群から選ばれる一以上である固形製剤A solid preparation characterized by containing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g / ml or more and a hard bulk density of 0.60 g / ml or more and sugar / sugar alcohol, the sugar-sugar alcohol, erythritol, sorbitol, solid preparation is trehalose, xylitol, mannitol, one or more selected from glucose or Ranaru group ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上で、かつ乾式レーザー回折法による体積平均粒子径が30ミクロン以上である低置換度ヒドロキシプロピルセルロースを粉砕して得られる該回折法による体積平均粒子径が25ミクロン以下の低置換度ヒドロキシプロピルセルロース及び糖・糖アルコールを含有することを特徴とする固形製剤であって、上記糖・糖アルコールが、エリスリトール、ソルビトール、トレハロース、キシリトール、マンニトール、グルコースからなる一群から選ばれる一以上である固形製剤。A low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g / ml or more, a hardened bulk density of 0.60 g / ml or more, and a volume average particle diameter of 30 microns or more by dry laser diffraction is pulverized. A solid preparation containing a low-substituted hydroxypropylcellulose having a volume average particle diameter of 25 microns or less and a sugar / sugar alcohol obtained by the diffraction method, wherein the sugar / sugar alcohol is erythritol, sorbitol, trehalose, xylitol, mannitol, solid preparation is one or more selected from glucose or Ranaru group. 上記糖・糖アルコールの平均粒子径が、500ミクロン以下である請求項1又は請求項2に記載の固形製剤。  The solid preparation according to claim 1 or 2, wherein the sugar / sugar alcohol has an average particle size of 500 microns or less. 上記低置換度ヒドロキシプロピルセルロースのヒドロキシプロポキシル基含量が、5.0〜16.0重量%であることを特徴とする請求項1〜3のいずれかに記載の固形製剤。  The solid preparation according to any one of claims 1 to 3, wherein the hydroxypropoxyl group content of the low-substituted hydroxypropylcellulose is 5.0 to 16.0 wt%. 固形製剤の製造方法において、ゆるめ嵩密度が0.40g/ml以上で、かつ固め嵩密度が0.60g/ml以上である低置換度ヒドロキシプロピルセルロースと糖・糖アルコール、又は該低置換度ヒドメキシプロピルセルロースであって乾式レーザー回折法による体積平均粒子径が30ミクロン以上であるものを粉砕して得られた体積平均粒子径が25ミクロン以下の低置換度ヒドロキシプロピルセルロースと該糖・糖アルコールを混合させることを特徴とする固形製剤の製造方法であって、上記糖・糖アルコールが、エリスリトール、ソルビトール、トレハロース、キシリトール、マンニトール、グルコースからなる一群から選ばれる一以上である固形製剤の製造方法。In the method for producing a solid preparation, low substituted hydroxypropylcellulose and sugar / sugar alcohol having a loose bulk density of 0.40 g / ml or more and a solid bulk density of 0.60 g / ml or more, or the low substitution hydride Low substituted hydroxypropyl cellulose having a volume average particle size of 25 microns or less obtained by pulverizing mexypropyl cellulose having a volume average particle size of 30 microns or more by dry laser diffraction method and the sugar / sugar alcohol a method of manufacturing a solid preparation characterized by mixing the above sugar-sugar alcohol, erythritol, sorbitol, trehalose, xylitol, mannitol, the solid preparation is one or more selected from glucose or Ranaru group Production method.
JP2001074044A 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same Expired - Fee Related JP3698652B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001074044A JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000075092 2000-03-17
JP2000-75092 2000-03-17
JP2001074044A JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Publications (2)

Publication Number Publication Date
JP2001328948A JP2001328948A (en) 2001-11-27
JP3698652B2 true JP3698652B2 (en) 2005-09-21

Family

ID=26587734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001074044A Expired - Fee Related JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Country Status (1)

Country Link
JP (1) JP3698652B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412263A4 (en) * 2009-03-27 2013-03-06 Ykk Corp CONTINUOUS CLOSURE ELEMENT, CLOSURE HALF-CHAIN, AND METHOD FOR MANUFACTURING CONTINUOUS CLOSURE ELEMENT

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2151241E (en) 2007-04-26 2012-05-07 Toray Industries Stable solid preparation comprising 4,5-epoxymorphinan derivative
KR101565621B1 (en) 2009-01-26 2015-11-03 신에쓰 가가꾸 고교 가부시끼가이샤 Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412263A4 (en) * 2009-03-27 2013-03-06 Ykk Corp CONTINUOUS CLOSURE ELEMENT, CLOSURE HALF-CHAIN, AND METHOD FOR MANUFACTURING CONTINUOUS CLOSURE ELEMENT

Also Published As

Publication number Publication date
JP2001328948A (en) 2001-11-27

Similar Documents

Publication Publication Date Title
JP4748627B2 (en) Excipient
KR100571085B1 (en) Low-substituted hydroxypropyl cellulose-containing solid preparation and preparation method thereof
WO2000078292A1 (en) Quickly disintegrating solid preparations
JP5623275B2 (en) Directly tabletable dextrose
EP2007384B1 (en) Orodispersible domperidone tablets
ZA200501420B (en) Use of an aqueous solution of citric acid and a water-soluble sugare like lacitol as granulation liquid in the manufacture of tablets
RU2500388C2 (en) Orally dispersible mannitol
KR100972773B1 (en) Antacid and Laxative Tablets
JP4551627B2 (en) Method for producing orally disintegrating tablets
JP5552400B2 (en) Granules masking bitterness and unpleasant taste of herbal medicines and intraoral quick disintegrating tablets
JP5945191B2 (en) Intraoral quick disintegrating tablet
JP4015485B2 (en) Antacid / loose tablets
JP2001322927A (en) Low substituted hydroxypropylcellulose-containing solid preparation and production method thereof
JP3698652B2 (en) Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same
JP6092672B2 (en) Orally rapidly disintegrating tablets
JP5584509B2 (en) Orally disintegrating tablets
CN101401796A (en) Pramipexole orally disintegrating tablets and preparation method thereof
WO2007018057A1 (en) Tablet rapidly disintegrating in the oral cavity and method of producing the same
JPH05506238A (en) pharmaceutical formulations
US20130072578A1 (en) Orodispersible tablets of erythritol and isomalt
JP2006022060A (en) Antacid / loose water dispersion and tablets therefor
JP2008133294A (en) Tablet disintegrated in buccal cavity

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20040123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040130

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040330

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041130

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050127

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050322

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050329

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050705

R150 Certificate of patent or registration of utility model

Ref document number: 3698652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080715

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110715

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees